- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-CD36/ BDPLT10/ CHDS7 monoclonal antibody
Anti-CD36/ BDPLT10/ CHDS7 antibody for FACS & in-vivo assay
Go to CD36/CD36 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T76286-Ab-1/ GM-Tg-hg-T76286-Ab-2 | Anti-Human CD36 monoclonal antibody | Human |
| GM-Tg-rg-T76286-Ab-1/ GM-Tg-rg-T76286-Ab-2 | Anti-Rat CD36 monoclonal antibody | Rat |
| GM-Tg-mg-T76286-Ab-1/ GM-Tg-mg-T76286-Ab-2 | Anti-Mouse CD36 monoclonal antibody | Mouse |
| GM-Tg-cynog-T76286-Ab-1/ GM-Tg-cynog-T76286-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CD36 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T76286-Ab-1/ GM-Tg-felg-T76286-Ab-2 | Anti-Feline CD36 monoclonal antibody | Feline |
| GM-Tg-cang-T76286-Ab-1/ GM-Tg-cang-T76286-Ab-2 | Anti-Canine CD36 monoclonal antibody | Canine |
| GM-Tg-bovg-T76286-Ab-1/ GM-Tg-bovg-T76286-Ab-2 | Anti-Bovine CD36 monoclonal antibody | Bovine |
| GM-Tg-equg-T76286-Ab-1/ GM-Tg-equg-T76286-Ab-2 | Anti-Equine CD36 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T76286-Ab-1/ GM-Tg-hg-T76286-Ab-2; GM-Tg-rg-T76286-Ab-1/ GM-Tg-rg-T76286-Ab-2; GM-Tg-mg-T76286-Ab-1/ GM-Tg-mg-T76286-Ab-2; GM-Tg-cynog-T76286-Ab-1/ GM-Tg-cynog-T76286-Ab-2; GM-Tg-felg-T76286-Ab-1/ GM-Tg-felg-T76286-Ab-2; GM-Tg-cang-T76286-Ab-1/ GM-Tg-cang-T76286-Ab-2; GM-Tg-bovg-T76286-Ab-1/ GM-Tg-bovg-T76286-Ab-2; GM-Tg-equg-T76286-Ab-1/ GM-Tg-equg-T76286-Ab-2 |
| Products Name | Anti-CD36 monoclonal antibody |
| Format | mab |
| Target Name | CD36 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-CD36 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species CD36/ BDPLT10/ CHDS7 VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | vGMAP000500 | Human CD36 Adenovirus particle |
| ORF Viral Vector | pGMLV000435 | human CD36 Lentivirus plasmid |
| ORF Viral Vector | vGMLV000435 | human CD36 Lentivirus particle |
| ORF Viral Vector | pGMAP000500 | Human CD36 Adenovirus plasmid |
| ORF Viral Vector | pGMAD000077 | mouse Cd36 Adenovirus plasmid |
| ORF Viral Vector | pGMAAV000035 | mouse Cd36 AAV plasmid |
| ORF Viral Vector | vGMAD000077 | mouse Cd36 Adenovirus particle |
| ORF Viral Vector | vGMAAV000035 | mouse Cd36 AAV particle |
Target information
| Target ID | GM-T76286 |
| Target Name | CD36 |
| Gene ID | 948,12491,574296,475931,101093842,281052,100049847 |
| Gene Symbol and Synonyms | BDPLT10,CD36,CHDS7,FAT,GP3B,GP4,GPIIIB,GPIV,PAS-4,PASIV,SCARB3 |
| Uniprot Accession | P16671,P26201 |
| Uniprot Entry Name | CD36_HUMAN,CD36_BOVIN |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target |
| Disease | Cancer |
| Gene Ensembl | ENSG00000135218 |
| Target Classification | Tumor-associated antigen (TAA) |
The target: CD36, gene name: CD36, also named as BDPLT10, CHDS7, FAT, GP3B, GP4, GPIV, PASIV, SCARB3. The protein encoded by this gene is the fourth major glycoprotein of the platelet surface and serves as a receptor for thrombospondin in platelets and various cell lines. Since thrombospondins are widely distributed proteins involved in a variety of adhesive processes, this protein may have important functions as a cell adhesion molecule. It binds to collagen, thrombospondin, anionic phospholipids and oxidized LDL. It directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes and it binds long chain fatty acids and may function in the transport and/or as a regulator of fatty acid transport. Mutations in this gene cause platelet glycoprotein deficiency. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Feb 2014].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
